Evaluation of Pharmacokinetics, clinical efficacy and Innate Immunity response of T-cells count and Cytokine (IFN gamma/IL-2) on oral administration of Agastya haritaki rasayana in chronic obstructive pulmonary disorder (COPD)

Chronic Obstructive Pulmonary Disease (COPD) is a progressive inflammatory airway disorder associated with repeated exacerbations and high morbidity. Conventional treatments mainly provide symptomatic relief and limited immune modulation. Agastya Haritaki Rasayana (AHR), a classical Ayurvedic formulation indicated in respiratory disorders, is traditionally used for Kasa and Shwasa but lacks scientific validation regarding its pharmacokinetics and molecular immune effects.